BMS’ ELOQUENT-1 Phase III study fails to meet primary endpoint
The primary endpoint of the study was to determine whether the addition of Empliciti to Revlimid and low-dose dexamethasone would improve progression-free survival. Credit: KGH.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more